Aliases & Classifications for Spasticity

MalaCards integrated aliases for Spasticity:

Name: Spasticity 54 29 6

Summaries for Spasticity

NINDS : 54 Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness of muscle, which might  interfere with movement, speech, or be associated with discomfort or pain.  Spasticity is usually caused by damage to nerve pathways within the brain or spinal cord that control muscle movement. It may occur in association with spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Symptoms may include hypertonicity (increased muscle tone), clonus (a series of rapid muscle contractions), exaggerated deep tendon reflexes, muscle spasms, scissoring (involuntary crossing of the legs), and fixed joints (contractures). The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity can interfere with rehabilitation in patients with certain disorders, and often interferes with daily activities.

MalaCards based summary : Spasticity is related to spastic paraplegia 15, autosomal recessive and spastic paraplegia 30, autosomal recessive. An important gene associated with Spasticity is DARS (Aspartyl-TRNA Synthetase). The drugs Menthol and Memantine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and t cells.

Wikipedia : 76 Spasticity (from Greek spasmos-, meaning \'drawing, pulling\') is a feature of altered skeletal muscle... more...

Related Diseases for Spasticity

Diseases related to Spasticity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 800)
# Related Disease Score Top Affiliating Genes
1 spastic paraplegia 15, autosomal recessive 34.0 SPG7 TECPR2
2 spastic paraplegia 30, autosomal recessive 34.0 KIF1A WASHC5
3 spastic paraplegia 49, autosomal recessive 33.8 SPG7 TECPR2
4 spastic paraplegia 73, autosomal dominant 33.4 CAPN1 SPG7
5 spastic paraparesis 33.1 DDHD1 SPG7 TECPR2
6 spastic paraplegia 76, autosomal recessive 33.0 CAPN1 SPG7
7 spastic ataxia 32.8 SACS SPG7
8 hereditary spastic paraplegia 32.2 CAPN1 DDHD1 KIF1A SACS SPG7 WASHC5
9 paraplegia 31.2 DDHD1 KIF1A SPG7 WASHC5
10 microcephaly 27.9 FAR1 PCDH12 SLC1A4 SLC2A1
11 spastic paraplegia 20, autosomal recessive 12.4
12 spastic paraplegia 2, x-linked 12.4
13 spastic paraplegia 7, autosomal recessive 12.4
14 spastic paraplegia 17, autosomal dominant 12.3
15 spastic ataxia, charlevoix-saguenay type 12.3
16 spastic paraplegia 11, autosomal recessive 12.3
17 spastic paraplegia 3, autosomal dominant 12.3
18 tropical spastic paraparesis 12.3
19 spastic hemiplegia 12.3
20 spastic paraplegia 56, autosomal recessive 12.2
21 spastic diplegia 12.2
22 spastic quadriplegia 12.2
23 spastic paraplegia, optic atrophy, and neuropathy 12.2
24 spastic paraplegia 26, autosomal recessive 12.2
25 spastic paraplegia 23 12.2
26 spastic paraplegia 35, autosomal recessive 12.2
27 spastic paraplegia 4, autosomal dominant 12.2
28 spastic paraplegia 72, autosomal recessive 12.2
29 spastic paraplegia 54, autosomal recessive 12.2
30 spastic paraplegia 9a, autosomal dominant 12.2
31 spastic cerebral palsy 12.2
32 spastic paraplegia 43, autosomal recessive 12.2
33 spastic paraplegia 39, autosomal recessive 12.2
34 spastic paraplegia 11 12.2
35 spastic paraplegia 10, autosomal dominant 12.2
36 spastic paraplegia 4 12.2
37 spastic paraplegia 53, autosomal recessive 12.2
38 spastic paraplegia 5a, autosomal recessive 12.2
39 spastic paraplegia 8, autosomal dominant 12.2
40 spastic paraplegia 48, autosomal recessive 12.2
41 spastic paraplegia 28, autosomal recessive 12.2
42 spastic paraplegia 6, autosomal dominant 12.2
43 infantile-onset ascending hereditary spastic paralysis 12.2
44 spastic paraplegia 45, autosomal recessive 12.2
45 spastic paraplegia 57, autosomal recessive 12.1
46 spastic paraplegia 12, autosomal dominant 12.1
47 spastic paraplegia 46, autosomal recessive 12.1
48 spastic paraplegia 55, autosomal recessive 12.1
49 spastic paraplegia 5a 12.1
50 spastic paraplegia 61, autosomal recessive 12.1

Graphical network of the top 20 diseases related to Spasticity:



Diseases related to Spasticity

Symptoms & Phenotypes for Spasticity

Drugs & Therapeutics for Spasticity

Drugs for Spasticity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 303)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
2
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
3
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
4
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Baclofen Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1134-47-0 2284
7
Tizanidine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51322-75-9 5487
8
Levodopa Approved Phase 4 59-92-7 6047
9
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
10
gamma-Aminobutyric acid Approved, Investigational Phase 4,Not Applicable 56-12-2 119
11
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
12
Sulfamethoxazole Approved Phase 4 723-46-6 5329
13
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
14
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2 4205-90-7 2803
15
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
16
Cefixime Approved, Investigational Phase 4 79350-37-1 54362 5362065
17
Norepinephrine Approved Phase 4 51-41-2 439260
18
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
19 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
20
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
21
Fosfomycin Approved Phase 4 23155-02-4 446987
22
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078
23
Peppermint oil Approved, Investigational Phase 4,Phase 3 8006-90-4
24
Peppermint Approved, Nutraceutical Phase 4,Phase 3
25 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 calcium channel blockers Phase 4,Phase 3,Not Applicable
28 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Adrenergic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
31 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
36 Neurotransmitter Uptake Inhibitors Phase 4,Phase 1,Not Applicable
37 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Dihydroxyphenylalanine Phase 4
40 Parasympatholytics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2
42 Dopamine Agents Phase 4,Not Applicable
43 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
45 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Not Applicable
46 Excitatory Amino Acids Phase 4,Phase 2,Not Applicable
47 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
48 Antidepressive Agents Phase 4,Phase 1,Phase 2,Not Applicable
49 Antidepressive Agents, Second-Generation Phase 4,Phase 1,Not Applicable
50 incobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 803)
# Name Status NCT ID Phase Drugs
1 Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity Unknown status NCT02757404 Phase 4
2 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
3 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
4 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
5 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
6 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
7 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
8 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
9 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
10 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
11 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
12 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
13 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
14 Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression Completed NCT02321436 Phase 4 BotulinumtoxinA;Placebo
15 SISTERS: Spasticity In Stroke Study - Randomized Study Completed NCT01032239 Phase 4 intrathecal baclofen
16 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
17 Vanderbilt University Spasticity Management Program Evaluation Plan Completed NCT00179114 Phase 4 Botulinum Toxin Type A;Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
18 Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity Completed NCT00234546 Phase 4 Botulinum toxin type A (Dysport®)
19 Memantine for Spasticity in MS Patients Completed NCT00638027 Phase 4 placebo;memantine
20 Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot Completed NCT03044080 Phase 4 IncobotulinumtoxinA;OnabotulinumtoxinA
21 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity Completed NCT00430196 Phase 4 BOTOX®;Zanaflex®
22 BOTOX® Economic Spasticity Trial (BEST) Completed NCT00549783 Phase 4
23 Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm Completed NCT00216411 Phase 4 Botulinum type A toxin (Dysport)
24 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
25 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
26 Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation-pilot Study Completed NCT03549975 Phase 4 Botulinum Toxin Type A 100 unit/Vial (Product)
27 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
28 Botulinum Toxin A Adult Gastrocnemius Muscle Study Completed NCT01278576 Phase 4 BOTOX-A®
29 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
30 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
31 Τhe Effectiveness of Hydrotherapy Exercises on the Rehabilitation of Hemiplegic Patients Completed NCT01460277 Phase 4
32 Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury Completed NCT00252954 Phase 4 Levetiracetam
33 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
34 Tizanidine and Superficial Cervical Block on Pain After Thyroidectomy Completed NCT02725359 Phase 4 Placebo;Tizanidine;Bupivacaine;Saline
35 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
36 Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder Completed NCT01388413 Phase 4 Weekly Oral Cyclic Antibiotic programme
37 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
38 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
39 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
40 Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings Recruiting NCT03302741 Phase 4 Botulinum neurotoxin (BTX)
41 Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment Recruiting NCT02462317 Phase 4 botulinum A toxin;Baclofen;Placebo toxin;placebo baclofen
42 Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity Recruiting NCT03517319 Phase 4 Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
43 The Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following Stroke Recruiting NCT02944929 Phase 4
44 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination Recruiting NCT03367429 Phase 4 Botox
45 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
46 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
47 Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC) Active, not recruiting NCT02969356 Phase 4 AbobotulinumtoxinA (Dysport®)
48 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
49 Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing Dynamic Hand Splinting in Adults With Post-stroke Hemiplegia (Orthox) Not yet recruiting NCT02888548 Phase 4
50 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4

Search NIH Clinical Center for Spasticity

Genetic Tests for Spasticity

Genetic tests related to Spasticity:

# Genetic test Affiliating Genes
1 Spasticity 29

Anatomical Context for Spasticity

MalaCards organs/tissues related to Spasticity:

41
Spinal Cord, Brain, T Cells, Testes, Bone, Skeletal Muscle, Cortex

Publications for Spasticity

Articles related to Spasticity:

(show top 50) (show all 3526)
# Title Authors Year
1
Pathogenic Variant of REEP1 in a Korean Family with Autosomal-Dominant Hereditary Spastic Paraplegia. ( 29629531 )
2018
2
Optimizing the management of spasticity in people with spinal cord damage: a clinical care pathway for assessment and treatment decision-making from the Ability Network, an international initiative. ( 29428347 )
2018
3
O 026 - Negative impact of muscle weakness and spasticity on gait in children with unilateral cerebral palsy. ( 29954655 )
2018
4
Ultrasound Strain Imaging to Assess the Biceps Brachii Muscle in Chronic Poststroke Spasticity. ( 29399851 )
2018
5
Bilateral Bicondylar Osteochondritis Dissecans in a Child with Spastic Diplegia and Crouch Gait: A Case Report. ( 29952775 )
2018
6
Title: Quantifying the change of spasticity after intrathecal baclofen administration: A descriptive retrospective analysis. ( 29913361 )
2018
7
Assessing mobility and balance in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay population: Validity and reliability of four outcome measures. ( 29801904 )
2018
8
Autosomal-dominant early-onset spastic paraparesis with brain calcification due to IFIH1 gain-of-function. ( 29782060 )
2018
9
Evaluation of independent versus integrated effects of reciprocal electrical stimulation and botulinum toxin-A on dynamic limits of postural stability and ankle kinematics in spastic diplegia: a single-blinded randomized trial. ( 29904047 )
2018
10
Phenol neurolysis for management of shoulder spasticity in early recovery from traumatic brain injury - a case report. ( 29933094 )
2018
11
A novel heterozygous variant in ERLIN2 causes autosomal dominant pure hereditary spastic paraplegia. ( 29528531 )
2018
12
Resting state fMRI studies in SPG4-linked hereditary spastic paraplegia. ( 29249364 )
2018
13
Expanding the <i>ADCY5</i> phenotype toward spastic paraparesis: A mutation in the M2 domain. ( 29473048 )
2018
14
Targeted next-generation sequencing improves diagnosis of hereditary spastic paraplegia in Chinese patients. ( 29934652 )
2018
15
Quantification of dysarthrI?phonia in a Cypriot family with autosomal recessive hereditary spastic paraplegia associated with a homozygous SPG11 mutation. ( 29804168 )
2018
16
Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms. ( 29449262 )
2018
17
Medial gastrocnemius structure and gait kinetics in spastic cerebral palsy and typically developing children: A cross-sectional study. ( 29794756 )
2018
18
Dynamic spasticity determines hamstring length and knee flexion angle during gait in children with spastic cerebral palsy. ( 29960141 )
2018
19
Gastrointestinal and urinary complaints in adults with hereditary spastic paraparesis. ( 29661209 )
2018
20
Corrigendum to &amp;quot;Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia&amp;quot; [Clin. Neurol. Neurosurg. 168 (May) (2018) 60-63]. ( 29970275 )
2018
21
Learning to cope with mirror movements in unilateral spastic cerebral palsy: a brief report. ( 29787338 )
2018
22
A hereditary spastic paraplegia-associated atlastin variant exhibits defective allosteric coupling in the catalytic core. ( 29180453 )
2018
23
CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56. ( 29034544 )
2018
24
Reply: POLR3A variants in hereditary spastic paraplegia and ataxia. ( 29236946 )
2018
25
Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. ( 29423615 )
2018
26
Quantitative Evaluation of Post-stroke Spasticity Using Neurophysiological and Radiological Tools: A Pilot Study. ( 29961736 )
2018
27
Collaborative Science Unites Researchers and a Novel Spastic Ataxia Gene. ( 29908061 )
2018
28
Generating the Visual Biofeedback Signals Applicable to Reduction of Wrist Spasticity: A Pilot Study on Stroke Patients. ( 29942436 )
2018
29
Dorsal rhizotomy for children with spastic diplegia of cerebral palsy origin: usefulness of intraoperative monitoring. ( 29652243 )
2018
30
Effectiveness of Faradic and Russian currents on plantar flexor muscle spasticity, ankle motor recovery, and functional gait in stroke patients. ( 29417699 )
2018
31
Treatment patterns of in-patient spasticity medication use after traumatic spinal cord injury: a prospective cohort study. ( 29904191 )
2018
32
Impact of spasticity on transfers and activities of daily living in individuals with spinal cord injury. ( 29334339 )
2018
33
Assessment of Spasticity by a Pendulum Test in SCI Patients Who Exercise FES Cycling or Receive Only Conventional Therapy. ( 29324409 )
2018
34
Trunk control and functionality in children with spastic cerebral palsy. ( 29652201 )
2018
35
Early AbobotulinumtoxinA (Dysport<sup>Ar</sup>) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. ( 29933562 )
2018
36
Effects of ultrasound-guided botulinum toxin type-A injections with a specific approach in spastic cerebral palsy. ( 29694645 )
2018
37
Muscle morphology of the lower leg in ambulant children with spastic cerebral palsy. ( 29981242 )
2018
38
The dosage and administration of long-term intrathecal baclofen therapy for severe spasticity of spinal origin. ( 29895878 )
2018
39
Comparison of Single-Session Dose Response Effects of Whole Body Vibration on Spasticity and Walking Speed in Persons with Spinal Cord Injury. ( 29959653 )
2018
40
Identification of specific gait patterns in patients with cerebellar ataxia, spastic paraplegia, and Parkinson's disease: A non-hierarchical cluster analysis. ( 28967438 )
2018
41
<i>ACO2</i> homozygous missense mutation associated with complicated hereditary spastic paraplegia. ( 29577077 )
2018
42
Quantitative Ultrasound Imaging to Assess the Biceps Brachii Muscle in Chronic Post-Stroke Spasticity: Preliminary Observation. ( 29398131 )
2018
43
Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). ( 29968200 )
2018
44
Supplemental Stimulation Improves Swing Phase Kinematics During Exoskeleton Assisted Gait of SCI Subjects With Severe Muscle Spasticity. ( 29910710 )
2018
45
Hereditary spastic paraplegia. ( 29478605 )
2018
46
Slip avoidance strategies in children with bilateral spastic cerebral palsy and crouch gait. ( 29679933 )
2018
47
Study of Knowledge, Attitude, and Practice in Participants with Regular Intake of Lathyrus, But No Spastic Paraparesis. ( 29456338 )
2018
48
Identification of a candidate enhancer for DMRT3 involved in spastic cerebral palsy pathogenesis. ( 29305858 )
2018
49
Balance, functional mobility, and fall occurrence in patients with human T-cell lymphotropic virus type-1-associated myelopathy/tropical spastic paraparesis: a cross-sectional study. ( 29768548 )
2018
50
GPT2 mutations cause developmental encephalopathy with microcephaly and features of complicated hereditary spastic paraplegia. ( 29882329 )
2018

Variations for Spasticity

ClinVar genetic disease variations for Spasticity:

6
(show all 11)
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XX;inv(2)(p23q31.3) inversion Pathogenic
2 Translocation Likely pathogenic
3 46;XX;inv(6)(p24q11)dn inversion Uncertain significance
4 KIF7 NM_198525.2(KIF7): c.434A> C (p.Tyr145Ser) single nucleotide variant Likely pathogenic rs758361736 GRCh37 Chromosome 15, 90193067: 90193067
5 KIF7 NM_198525.2(KIF7): c.434A> C (p.Tyr145Ser) single nucleotide variant Likely pathogenic rs758361736 GRCh38 Chromosome 15, 89649836: 89649836
6 PMP22 NM_000304.3(PMP22): c.422T> G (p.Val141Gly) single nucleotide variant Uncertain significance rs1057518804 GRCh37 Chromosome 17, 15134295: 15134295
7 PMP22 NM_000304.3(PMP22): c.422T> G (p.Val141Gly) single nucleotide variant Uncertain significance rs1057518804 GRCh38 Chromosome 17, 15230978: 15230978
8 SPAST NM_014946.3(SPAST): c.1276C> T (p.Leu426Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs1060502227 GRCh38 Chromosome 2, 32136593: 32136593
9 SPAST NM_014946.3(SPAST): c.1276C> T (p.Leu426Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs1060502227 GRCh37 Chromosome 2, 32361662: 32361662
10 CREBBP NM_004380.2(CREBBP): c.6185_6195delTCTCACCCAGC (p.Ile2062Serfs) deletion Likely pathogenic GRCh37 Chromosome 16, 3778853: 3778863
11 CREBBP NM_004380.2(CREBBP): c.6185_6195delTCTCACCCAGC (p.Ile2062Serfs) deletion Likely pathogenic GRCh38 Chromosome 16, 3728852: 3728862

Expression for Spasticity

Search GEO for disease gene expression data for Spasticity.

Pathways for Spasticity

GO Terms for Spasticity

Cellular components related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon cytoplasm GO:1904115 8.62 KIF1A SPG7

Biological processes related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anterograde axonal transport GO:0008089 8.62 KIF1A SPG7

Sources for Spasticity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....